Clover Corporation (CLV) H1 2026 earnings summary

Executive summary

• Revenue for the half-year reached AUD 44.1 million, up 17% or AUD 6.5 million year-over-year, driven by new customers, product diversification, and improved market conditions.

• EBITDA rose to AUD 6.9 million, up AUD 2.6 million year-over-year, supported by new products, manufacturing efficiencies, and favorable product mix.

• Net profit after tax increased to AUD 4.2 million, up AUD 1.8 million or 79% year-over-year, reflecting strong operational performance and margin improvement.

• Gross margin improved to 35.6%, reflecting a diversified product mix and operational improvements.

• Cash balance at period end was AUD 10.3 million, with no bank debt.

Financial highlights

• Revenue reached a record AUD 44.1 million for the half, up 17% from the previous period.

• Gross margin improved to 35.6%, up from 30.4% last year.

• EBITDA was AUD 6.9 million, an increase of AUD 2.6 million year-over-year.

• NPAT was AUD 4.2 million, up 75–90% year-over-year, with return on sales at 9.6%.

• EPS increased to 2.54 cents per share, up from 1.42 cents per share.

Outlook and guidance

• Full-year revenue guidance set at AUD 92–96 million, anticipating a record year.

• Positive momentum expected to continue into the second half, with strong demand forecasts.

• Guidance assumes stable geopolitical conditions and supply chains.

• Choline product expected to generate revenue in the next financial year after ongoing trials and regulatory outcomes.